IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 125 filers reported holding IMMUNOVANT INC in Q1 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,310,678 | +30.5% | 372,771 | -35.5% | 0.02% | +33.3% |
| Q2 2023 | $10,967,221 | +6.2% | 578,135 | -13.2% | 0.01% | 0.0% |
| Q1 2023 | $10,326,325 | +3147.3% | 665,785 | +9565.9% | 0.01% | – |
| Q4 2020 | $318,000 | +55.1% | 6,888 | +18.5% | 0.00% | – |
| Q3 2020 | $205,000 | – | 5,815 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alpine Global Management, LLC | 4,448,017 | $17,347,000 | 4.39% |
| Deep Track Capital, LP | 9,455,000 | $36,875,000 | 2.42% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 233 | $60,000,000 | 0.63% |
| Octagon Capital Advisors LP | 579,061 | $2,258,000 | 0.60% |
| Eventide Asset Management | 5,372,512 | $20,953,000 | 0.45% |
| WITTENBERG INVESTMENT MANAGEMENT, INC. | 174,000 | $679,000 | 0.29% |
| Frazier Life Sciences Management, L.P. | 585,759 | $2,284,000 | 0.22% |
| BCK CAPITAL MANAGEMENT LP | 54,293 | $212,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 777,590 | $3,033,000 | 0.12% |
| Bridgefront Capital, LLC | 15,649 | $61,000 | 0.07% |